A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT00652366 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

467

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Erlotinib, escalating dose
DRUG: Erlotinib, standard dose
DRUG: Gemcitabine

Sponsor

Hoffmann-La Roche